Results 81 to 90 of about 39,159 (175)

Prolonged Persistence of Lamivudine-resistant Mutant and Emergence of New Lamivudine-resistant Mutants Two Years After Lamivudine Withdrawal in HBsAg-positive Chronic Hepatitis Patient: A Case Report

, 2008
Lamivudine can select resistant hepatitis B virus (HBV) tyrosine-methionine-aspartate-aspartate aminoacid motif (YMDD) mutants, which usually disappear in few months after lamivudine withdrawal.
D'ONOFRIO M, TOSONE, GRAZIA, ORLANDO, RAFFAELE, VEROPALUMBO E, PORTELLA, GIUSEPPE, PIAZZA, MARCELLO   +5 more
core   +1 more source

Unusual case of lamivudine-associated skin rashes in an HIV/AIDS patient: a case presentation

Archives of Pharmacy Practice, 2017
In patients with human immunodeficiency virus (HIV) infection, lamivudine is used as a first-line drug for antiretroviral therapy. Lamivudine is relatively nontoxic in nature, and it can also be used during pregnancy.
Kashif U Khan, Amer H Khan, Syed A Sulaiman, Chow T Soo, Syed I Ahmad   +4 more
doaj   +1 more source

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children [PDF]

, 2007
: Objective: To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial. Design: PENTA 5 was a 48-week randomised controlled trial
COMPAGNUCCI A, LEVY J, FEITERNA SPERLING C, BUTLER K, WALKER AS, WINTERGERST U, GIBB DM, GIAQUINTO, CARLO, SAIDI Y, DE ROSSI, ANITA, HARPER L, CANDEIAS E, CASTELLI GATTINARA G, PILLAY D, DELLA NEGRA M, Paediatric European Network for the Treatment of AIDS, GREEN H   +16 more
core  

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)

, 2006
Objective: We compared the immunological and clinical outcomes of lamivudine monotherapy and complete therapy interruption in the treatment of HIV-1-infected patients harbouring lamivudine-resistant virus.
CLEMENTI, MASSIMO, Boeri, E, Galli, A, Galli, L, Gianotti, N, Cernuschi, M, CASTAGNA, ANTONELLA, Hasson, H, LAZZARIN, ADRIANO, Menzo, S, Carini, E, Danise, A   +11 more
core   +1 more source

Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort. [PDF]

, 2005
Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established.
Araki, Yasuyuki, Shiratori, Yasushi, Sakaguchi, Kohsaku, Piao, Cheng-Yu, Senoh, Tomonori, Kobashi, Haruhiko, Kaneyoshi, Toshihiko, Iwasaki, Yoshiaki, Fujio, Kozo, Terada, Ryo, Hashimoto, Kuniaki, Fujioka, Shin-ichi, Nishida, Tomohiro   +12 more
core   +1 more source

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials

BMC Infectious Diseases, 2011
Background Interferon alpha (IFNα) therapy has been widely used in the treatment of chronic hepatitis B (CHB) for decades. Nucleos(t)ide analogues are also increasingly used to treat CHB recently.
Zhang Yu-guo, Ren Wei-guang, Kong Ling-bo, Wang Mao-rong, Li Wen-cong, Nan Yue-min   +5 more
doaj   +1 more source

Lamivudine in the treatment of HBV-related liver disease after renal transplantation: an update

, 2005
Diminished survival due to hepatitis B has been observed after renal transplantation (RT). Lamivudine, a second-generation nucleoside analogue, has been approved for the treatment of chronic hepatitis B virus (HBV) infection in patients with normal ...
Bunnapradist, S, Fabrizi, F, E. Rusconi, Villa, M, P.G. Messa, Messa, P.G, Martin, P, P. Martin, S. Bunnapradist, F. Fabrizi, M. Villa, Rusconi, E, Fabrizi F, Villa M, Martin P, Bunnapradist S, Messa P, Rusconi E   +17 more
core   +2 more sources

Overlap Lamivudine Treatment in Patients with Chronic Hepatitis B Receiving Adefovir for Lamivudine-Resistant Viral Mutants

, 2009
Adefovir dipivoxil is effective against lamivudine-resistant hepatitis B virus (HBV) strains. Whether short-term overlap lamivudine is beneficial remains unknown, particularly in patients with decompensated chronic hepatitis B.
LIU, CHUN-JEN;KAO, JIA-HORNG;CHEN, PEI-JER;CHEN, T-C;LIN, FANG-YUE;LAI, MING-YANG;CHEN, DING-SHINN, 劉俊人;高嘉宏;陳培哲;陳聰智;林芳郁;賴明陽;陳定信   +1 more
core  

Detection of the YMDD Motif Mutations Rate in Chronic Hepatitis B Patients Treated with Lamivudine

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum, 2011
Background and Objectives: Lamivudine is the first nucleoside analogue licensed for the treatment of chronic hepatitis B patients which is effective in suppressing virus replication and results in reduced disease activity.
R Rafiei Tabatabaei, R Ehsani, A Pouryasin, A Soudbakhsh, H Sharafi   +4 more
doaj  

Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B

Brazilian Journal of Infectious Diseases
BACKGROUND AND AIM: Chronic hepatitis B is a highly prevalent disease worldwide, leading to serious consequences if not properly treated. Six treatment options for chronic hepatitis B are currently provided by the Brazilian public health system ...
Astrid Wiens, Rafael Venson, Cassyano Januário Correr, Roberto Pontarolo   +3 more
doaj   +1 more source